Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the need for additional studies.

FDA reports shortage of Novo Nordisk’s weight loss drug Saxenda

Novo Nordisk is facing another shortage of one of its blockbuster drugs; this time it’s the weight loss drug liraglutide, better known as Saxenda. According

July 21, 2023

Methadone treatment gets first major update in over 20 years

The federal government is unveiling new regulations meant to modernize methadone treatment, the first major update to patient care standards at methadone clinics in more

February 1, 2024

Non-Erosive GERD May Not Increase Risk of Esophageal Cancer

Patients with non-erosive gastroesophageal reflux disease (GERD) appear to have a similar incidence of esophageal adenocarcinoma as the general population, according to a large Nordic

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.